Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

March 30, 2015

Primary Completion Date

September 30, 2021

Study Completion Date

March 31, 2023

Conditions
Metastatic MelanomaRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorRecurrent Hodgkin LymphomaRecurrent Malignant Solid NeoplasmRecurrent MelanomaRecurrent NeuroblastomaRecurrent Non-Hodgkin LymphomaRecurrent OsteosarcomaRecurrent RhabdomyosarcomaRefractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorRefractory Hodgkin LymphomaRefractory Malignant Solid NeoplasmRefractory MelanomaRefractory NeuroblastomaRefractory Non-Hodgkin LymphomaRefractory OsteosarcomaRefractory RhabdomyosarcomaStage III Cutaneous Melanoma AJCC v7Stage IIIA Cutaneous Melanoma AJCC v7Stage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7Unresectable Melanoma
Interventions
BIOLOGICAL

Ipilimumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

OTHER

Pharmacological Study

Correlative studies

Trial Locations (25)

10032

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

20010

Children's National Medical Center, Washington D.C.

20892

National Institutes of Health Clinical Center, Bethesda

30322

Children's Healthcare of Atlanta - Egleston, Atlanta

35233

Children's Hospital of Alabama, Birmingham

38105

Saint Jude Children's Research Hospital, Memphis

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

Riley Hospital for Children, Indianapolis

48109

C S Mott Children's Hospital, Ann Arbor

53226

Children's Hospital of Wisconsin, Milwaukee

55455

University of Minnesota/Masonic Cancer Center, Minneapolis

60611

Lurie Children's Hospital-Chicago, Chicago

63110

Washington University School of Medicine, St Louis

77030

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston

80045

Children's Hospital Colorado, Aurora

90027

Children's Hospital Los Angeles, Los Angeles

92868

Children's Hospital of Orange County, Orange

94158

UCSF Medical Center-Mission Bay, San Francisco

94304

Lucile Packard Children's Hospital Stanford University, Palo Alto

97239

Oregon Health and Science University, Portland

98105

Seattle Children's Hospital, Seattle

02215

Dana-Farber Cancer Institute, Boston

M5G 1X8

Hospital for Sick Children, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02304458 - Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | Biotech Hunter | Biotech Hunter